• Artificial intelligence (AI) at forefront of scientific discovery, proving importance in fighting complex diseases
• Science turns to AI as effective tool to help find COVID-19 vaccines and therapeutics
• Predictive Oncology harnesses power of AI to improve cancer patient outcomes

With the global onslaught of COVID-19, scientists are harnessing the speed and power of artificial intelligence (AI) to find solutions. The complexity of this lethal contagion demands a rapid yet comprehensive response, and only advanced computer systems can parse through mountains of data sets swiftly enough to stem the pandemic. AI’s ability to sort and sift data quickly, spot patterns and make predictions can help identify both potential vaccines and therapeutics. Predictive Oncology Inc. (NASDAQ: POAI) is utilizing its proprietary AI solutions to understand and battle cancer – positioning the company as an attractive option for investors looking to invest in the future of cutting-edge medicine. These same AI solutions may be utilized to help find COVID-19 vaccines and therapeutics.

Through its subsidiary Helomics, a leader in AI and functional precision medicine, POAI is bringing its innovative technology to cancer research, where it’s working with the pharmaceutical, diagnostic and biotech industries to develop predictive models of how tumors respond to drugs, which can be used both for clinical decision support and research into new therapies.

The power and utility of artificial intelligence was delineated in a recent Wall Street Journal article titled ‘Biotech Companies Tap AI to Speed Path to Coronavirus Treatments’ (http://ibn.fm/iIeHT). While drug development – from invention to clinical trials – can take more than a year, health care industry leaders are looking to AI to identify drug prospects to test on humans within months. POAI’s predictive models can be applied clinically to aid patients and in the development of new drugs by researchers.

Aggressive situations like the steady spread of COVID-19, among other fast-moving cancers and diseases, has the global community scrambling for an expedited solution – a problem that AI-powered technology has the potential to help solve. “[COVID-19] is a rapidly developing situation, and we firmly believe that AI-driven experimentation is the right approach for these kinds of problems, to speed up the process,” stated professor Robert Murphy, Ph.D., a recognized expert in AI and computational biology. Dr. Murphy also sits on Predictive Oncology’s advisory board and is the head of the computational biology department in the School of Computer Science at Carnegie Mellon University and co-founder of AI predictive-modeling company Quantitative Medicine LLC.

In a pivotal collaborative move, Predictive Oncology has completed a letter of intent (http://ibn.fm/VRS4a) to acquire Quantitative Medicine and integrate its CoRE predictive modeling platform with POAI’s massive historic database and tumor profiling expertise with the aim of revolutionizing the way precision therapies are developed. The acquisition will provide POAI with Quantitative Medicine’s proven machine learning framework, CoRE. A predictive model-building platform for drug screening and optimization campaigns, CoRE uses hybrid machine learning approaches to rapidly build predictive models that spawn specific wet lab experiments. This cutting-edge technology, similar in methodology to the current AI and machine learning approaches now used in the battle against COVID-19, has the potential to expedite POAI’s mission to use AI and machine learning to discover unique solutions to the future of disease.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• SGLB recently awarded contract by the Mississippi State University Center for Advanced Vehicular Systems to install PrintRite3D software
• PrintRite3D (R) is sole solution for addressing in-process, quality-control issues for 3D metal printing
• Project demonstrates ability of PrintRite3D to serve as real-world testing ground
• Current addressable market for quality-assurance software is $1.4 billion, expected to reach $3.9 billion by 2023

Sigma Labs Inc. (NASDAQ: SGLB), a leading provider of quality-assurance software for the 3D-metal-printing industry, was recently awarded a contract by the Mississippi State University Center for Advanced Vehicular Systems (CAVS), a leading interdisciplinary research center that addresses challenges faced by U.S. mobility industries using state-of-the-art technology. The contract involves the installation of Sigma Lab’s PrintRite3D(R) on a Renishaw AM400 machine, further demonstrating the platform’s interoperability on an increasingly large base of AM machine manufacturers.

PrintRite3D is Sigma Labs’ patented, in-process, quality-assurance software for the commercial 3D-metal-printing industry, aiming to solve the in-process, quality-control issues that impede the industry from moving past the prototype phase. Because the 3D printing process involves the continuous layering of raw materials to form a 3D object, errors are currently found at the end of the production process during the inspection phase – often resulting in rejected output, lost time, wasted materials and lost profits.

PrintRite3D addresses this issue by providing real-time, melt-pool analytics, leveraging thermal signatures to monitor the quality of each part in the production process, layer by layer and in real time. This information allows operators to stop production of a defective part or employ corrections in-process, ultimately solving the quality consistency issues and giving producers the ability to economically scale up production with increased confidence.

CAVS is a world-class, premier automotive research center, employing more than 300 staff and researchers. Through the use of high-performance, computational resources and state-of-the-art analytical tools for modeling, simulation and experimentation, the center aims to solve some of the most pressing engineering challenges facing US mobility industries.

“They have agreed to act as a test bed for new product improvements to PrintRite3D, uniquely allowing us a real-world feedback loop to continuously improve our technology suite,” Sigma Labs Executive Chairman Mark K. Ruport stated in a news release. “I look forward to working with the entire team at CAVS to bring a new level of quality assurance to both their partners and the additive manufacturing industry as a whole.”

Besides partnerships in the educational sector, SGLB has a global client base that includes many tier-1 OEM enterprises and end users such as Siemens, Honeywell, and Pratt & Whitney. The company is currently in the execution and delivery phase of its commercial development with millions of dollars of investment focused on refining the latest version of PrintRite3D and protecting the IP.

Recognized as a technological game changer in the industry, SGLB’s software is being tested at 23 installations across 19 different users – some of which are the most recognized names in the industry. Currently estimated at a $1.4 billion addressable market, the provision of advanced-quality assurance software to the commercial 3D printing industry is expected to grow to $3.9 billion by 2023.

For more information about Sigma Labs, please visit www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

• Mineral exploration company Bolt Metals Corp., is advancing its focus on the acquisition and development of production-grade electric vehicle (EV) battery metals projects in the Asia-Pacific region
• EVs and their batteries are regarded widely by governments, industries and consumers as landmark-worthy solutions to global pollution and climate change concerns
• Indonesia is angling to become a world-leading supplier in the market for scarce EV battery metals such as nickel and cobalt, and nearby China is a major consumer
• Bolt’s flagship Cyclops property in Indonesia is a key part of its drive to be a player nickel and cobalt for the EV market
• A non-binding cooperative agreement between Bolt and Chinese metals producer Hunan Jinxin has opened the door to more definitive talks on a potential EV battery metals supply chain from the Cyclops property

A non-binding cooperative agreement between Canadian mineral exploration company Bolt Metals Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) and Chinese tungsten and cobalt producer Hunan Jinxin is paving the way for developing assets to serve Asia’s expanding electric vehicle production supply chain.

The cooperation agreement immediately allows the companies to begin negotiating definitive binding agreements with regards to Bolt’s 100 percent-controlled Cyclops Nickel-Cobalt facility based in Indonesia, where extensive exploration has previously taken place e, according to a March 5 news release (http://ibn.fm/62Vmz).

Nickel and cobalt are critical components of lithium-ion batteries that are experiencing a worldwide resource supply deficit in counterpoint to their popularity in helping the batteries to provide low-heat, lightweight, stable power supplies to computerized products.

Lithium-ion batteries have become a go-to solution for global climate change activism, in particular, as governments, industry and consumers worldwide seek ways to reduce the environment-polluting carbon emissions of automobiles, mass transportation vehicles and energy plants through the use of lithium-ion powered electric vehicles and storage batteries.

Bolt Metals’ flagship subsidiary employs an experienced, local workforce at a location close to air and sea transport links in Indonesia. The Cyclops project current has both its production and environmental permits and year around access for development.

A prior news release (http://ibn.fm/keByn) states that Cyclops’ mineralization-finding success has made it possible for the company to attract capital it needs “to pursue ambitious milestones in 2020, which include preparations to commission and operate a pilot process test plant in Canada, which will… then be used to establish the design criteria for the subsequent demonstration plant in Indonesia… and to establish the design criteria for a commercial scale plant.”

Bolt, formerly known as Pacific Rim Cobalt, has offices in Indonesia (Jakarta), China (Shanghai) and Canada (Vancouver).

Indonesia has been actively angling to become a dominant player in the electric vehicle cathode supply chain, thanks to its world-leading nickel reserves and closeness to the EV-hungry market in China.

“The business strategy can be designed in this country so that we can get ahead of others in building an inexpensive electric car industry, which is competitive because the raw materials are here,” Indonesian President Joko Widodo said during an event last August (http://ibn.fm/zcOj7).

The country aims to begin EV production in 2022 and to boost its share of EV production to 20 percent of total car output by 2025.

For more information, visit the company’s website at www.BoltMetals.com

NOTE TO INVESTORS: The latest news and updates relating to PCRCF are available in the company’s newsroom at http://ibn.fm/PCRCF

• Sigma Labs enters Joint Sales Agreement with industry leader Materialise to integrate, commercialize Sigma Labs’ Quality Assurance technology
• Momentous industry collaboration validates 3rd party in-process quality assurance’s critical role in adoption, acceleration of metal additive manufacturing (AM)
• SGLB’s PrintRite3D(R) is the only known technology that uniquely detects, identifies defects and anomalies real-time during 3D printing process of metal parts
• Sigma Labs looks to snag significant segment of an untapped $2 billion market

In a groundbreaking press release (http://ibn.fm/LsLEq), Sigma Labs Inc. (NASDAQ: SGLB) announced a joint sales agreement to commercialize SGLB’s PrintRite3D Quality Assurance technology which has been integrated with the Materialise Control Platform. Materialize NV (NASDAQ: MTLS) is a recognized global leader in 3D-printing software and advanced 3D printing services. The widely used Materialise Control Platform is an embedded hardware and software solution that provides better control over the additive manufacturing (AM) process by giving full control to the end-user.

Just last November, Sigma Labs demonstrated the latest version of its proprietary PrintRite3D Real-Time Melt Pool Analytics software platform in conjunction with Materialise at the Formnext 2019 conference in Frankfurt (http://ibn.fm/VTJrK). Since then, the companies have achieved integration of their products and now will offer a unique product solution for the entire metal additive manufacturing market: the retrofit of existing AM machines, OEM machine integration and closed loop control.

A myriad of variables, from machines to materials, create production challenges in AM. The inability to know the quality of finished products until postproduction and the uncertainty of parts being produced with consistency has limited companies’ ability to scale and has severely limited the widespread adoption of additive manufacturing.

Sigma Labs is determined to change that uncertainty by using artificial intelligence (AI) to predict flaws in the meltpool during production, providing quality assurance in-process, rather than post-process. Sigma’s PrintRite3D uniquely leverages thermal signatures to monitor the quality of each part in the production process – layer by layer and in real time. This allows operators to correct or stop production of a defective part, resulting in reduced error rates and higher yields. This incredibly sophisticated and powerful technology holds tremendous value for the 3D metal printing industry, and the Materialise agreement is a clear recognition of the value.

The agreement marks the first time a 3rd party in-process quality assurance software has been integrated and embedded in an AM platform, and perhaps more importantly, the agreement also marks the launch of Sigma Labs into commercialization. Founded in 2010 by a team of Los Alamos scientists, physicists and metallurgists, Sigma Labs has undergone extensive testing and validation of efficacy, earning high marks from all parties along the way.

SGLB is in an enviable position with a market projected to exceed $2 billion dollars, based on just the estimated number of 3D metal printers shipped between 2021 and 2027. Even more significant is Sigma’s competitive role in the $2 billion market, as no comparable is known to exist. Sigma Labs is the sole provider of real-time, in-process quality control software for the metal additive manufacturing market. Beyond the looming existing market, 3D printing is booming and projected to grow at a CAGR of 32.5% from 2019 to 2020 – and Sigma should be able ride the crest of that wave as well.

A large untapped market in search of solutions, a big technological head start, strategic partnerships and alliances in place, multiple patents awarded with more pending, and a reputation as the leading technology with significant barriers to entry from competition, Sigma Labs now surges to expand commercialization.

For more information about Sigma Labs, please visit www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

• InsuraGuest’s Hospitality Liability Policy covers a wide range of issues, from theft and damage of personal property to accidental medical expenses and accidental death and dismemberment
• Number of vacation rental users globally expected to soar to 793 million in 2020
• Vacation rental revenue stood at $57.669 billion last year with market growth rate of 6.9%

Hotel and vacation rental specialized insurance provider InsuraGuest Technologies Inc. (TSX.V: ISGI) is poised to flourish on the rapidly growing vacation rental market. The company recently announced the launch of InsuraGuest Insurance Agency, LLC (IG Agency), its wholly owned subsidiary. IG Agency is registered and licensed to sell insurance in several states nationwide and brings licensed insurance sales in-house to create shareholder value and increase InsuraGuest revenues.

The agency is expected to begin selling InsuraGuest’s specialized Hospitality Liability Policy in combination with the company’s InsurTech platform to hotels and vacation rental sectors nationwide in the second half of the year (http://ibn.fm/btd6h). The move will allow InsuraGuest to cement its position on the fast-growing vacation rental market, which it entered in September 2019.

Projected vacation rental revenue for 2019 was $57.669 billion with a market growth rate of 6.9 percent. U.S. travel to overseas markets totaled 35.1 million, up by 7 percent. Approximately 25 percent of Americans report engaging with short-term rental platforms (23 percent), up 277 percent from 6 percent (http://ibn.fm/fhnTY). According to Statista, the number of vacation rental users worldwide is expected to exceed 793 million, while the overall market is projected to go over $87 billion in 2020 (http://ibn.fm/FhkXd).

To further expand its reach across the U.S. and worldwide, InsuraGuest recently signed an international sales contract with world-famous hotelier Roger Bloss and his company Cal-Vegas, Inc., formed in 1996 to own and manage lodging facilities throughout the U.S. on behalf of third-party owners as well as for its own account. The contract with InsuraGuest will help Bloss leverage his vast network and experience to boost hotel sales and onboarding of InsuraGuest’s platform. The company’s InsurTech platform can integrate with around 71 different property management systems, giving it access to millions of rooms worldwide (http://ibn.fm/KjAei).

Traditional traveler’s insurance doesn’t cover a number of things that can happen inside hotels or other travel properties, putting both the traveler and the hotel or property owner at risk. People often mistakenly assume that accidents happening at such a property are covered by the property owner’s insurance, but that’s not always the case. InsuraGuest’s proprietary InsurTech software platform delivers a specialized Hospitality Liability policy to the hotel or vacation rental property to protect the guest during their stay while on the property. InsuraGuest is the first line of defense for the property and the guest. The specialized policy covers theft and damage of personal property, as well as accidental medical expenses and accidental death and dismemberment.

For more information, visit the company’s website at www.InsuraGuest.com

NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• PLUS was largest, best-selling infused gummies brand in California in 2019
• Launch of new Plus Products CBDRelief brand extends portfolio into wellness and relief market
• Company plans another successful launch in strategic pursuit to become the world’s strongest cannabis brand

Kleenex, Xerox, Coca-Cola: Through hyper-focused brand cultivation, these companies’ products have become symbols of their respective categories. As it strives to become the preferred edibles brand in the world, Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) is channeling this strategy, choosing a core product on which to build a strong brand name before branching out. As a result, Plus has become California’s preferred cannabis gummies brand of choice: After introducing its edible gummy line to the market in 2016, the company’s offerings reached top two spots in the highly competitive California market in less than two years.

Plus Products is working to offer high-quality edibles formulated to support a healthy and active lifestyle while still being accessible and affordable. The core PLUS brand was the largest cannabis-infused gummies brand with the best-selling cannabis product in California in 2019.

The company’s success is due in no small part to its product quality. Plus Products delivers a consistent, dosable and delicious cannabis experience. After proving its core brand in the highly competitive adult-market of California, the company is expanding its product line into the wellness and relief market segment. In February, PLUS announced the launch of a new Plus CBDRelief brand (http://ibn.fm/PkKVb).

“We have seen compelling success with our core brand and are excited to take the next step towards becoming a true portfolio of brands with the launch of PLUS CBDRelief,” PLUS co-founder and CEO Jake Heimark stated in a news release. “Last year we partnered with market structure research firm, HJR Associates, and found that when consumers used cannabis, over one-third of the time it was to address pain, stress or anxiety.”

Thus far, the wellness and relief market has been underserved, and PLUS sees an opportunity to provide an innovative product line for consumers who are looking for relief. The new line consists of two products: PLUS CBDRelief 9:1 Tropical Mango and PLUS CBDRelief 18:1 Tart Cherry. This new product line delivers the highest CBD content per package for gummies in the California marketplace while still maintaining the brand’s identity of precision dosing and high-quality products.

“Research suggests that people are looking to cannabis as a holistic tool for relief. It’s exciting to leverage rigorous science to formulate great products that enable people to help themselves,” stated PLUS Chief Scientific Officer Dr. Ari Mackler, in reference to proprietary research conducted by a third-party firm. “Research on cannabis is progressing quickly, and we are driving our portfolio of products with innovative science and technologies that will support our customers’ health and wellness goals.”

In Q3 2019, revenues were at $3.5 million – a 38% year-over year increase. That same quarter, PLUS launched a nationwide 100% hemp CBD edible line available online at PlusProducts.com. In Q4, PLUS continued with another successful launch, this time into Nevada’s adult-use cannabis market.

By building a brand and maintaining the top position for gummies for six quarters in the most competitive cannabis market in the world, PLUS has developed a strategy that works. The company’s launch of the CBDRelief brand is the next step in a strategic plan toward growth in making cannabis safe and approachable with high-quality products that deliver consistent consumer experiences.

Plus Products is now moving forward with its eyes on becoming the world’s strongest cannabis brand portfolio.

For more information, visit the company’s website at www.PlusProducts.com

NOTE TO INVESTORS: The latest news and updates relating to PLPRF are available in the company’s newsroom at http://ibn.fm/PLPRF

• POAI positioned as leader in using data, artificial intelligence in search for novel effective treatments
• Planned acquisition provides Predictive Oncology with CoRE(TM), a proven machine-learning framework
• Uniting CoRE with proprietary PDx tumor-profiling platform and tumor-data database creates one-of-a-kind, end-to-end “discovery machine”

With its recent proposed acquisition of Carnegie Mellon spin-out Quantitative Medicine, Predictive Oncology Inc. (NASDAQ: POAI), a leader in using data and artificial intelligence (AI) to develop personalized cancer therapies, demonstrates its strong position in assisting in the search for new anti-cancers, anti-virals, antibiotics and vaccines. POAI’s expertise in this area is particularly relevant in light of the current race to learn more about the novel coronavirus 2019-nCoV and identify potential treatments, including vaccines, to fight the COVID-19 disease.

As organizations around the world rush to find ways to slow the spread of the COVID-19 outbreak, the importance of AI and machine learning (ML) in the world of today’s medicine has become increasingly clear (http://ibn.fm/wekHx). Governments, pharmaceutical companies, universities and others are united in their focus to develop new diagnostics, vaccines and drug therapies aimed at the 2019-nCoV virus.

Announcements from Insilico Medicine and MIT point to the increasing importance of AI and ML in the progress of modern medicine. In addition, both studies relied on AI and ML approaches that are similar to the CoRE technology used by QM, which POAI is working to acquire (http://ibn.fm/VVfym). With an agreement in principal in place, the all-stock acquisition is expected to close this month.

This planned acquisition provides POAI with QM’s proven machine-learning framework, called CoRE. Developed at CMU and exclusively licensed to QM, CoRE is a predictive model-building platform for drug screening and optimization campaigns that uses hybrid machine-learning approaches to rapidly build predictive models to drive wet-lab experimentation.

Uniting the CoRE approach with the proprietary PDx tumor-profiling platform and tumor-data database owned by POAI subsidiary Helomics allows for a one-of-a-kind, end-to-end “discovery machine” (http://ibn.fm/RHsQS). This approach will “rapidly and cost-effectively generate potential therapeutic candidates that demonstrate activity against the disease. Therapeutic candidates developed by this iterative AI and experiment cycle can be fast-tracked, since there is already demonstrated activity in preclinical laboratory tests rather than just a computer model.”

Although POAI’s current focus is on cancers, the CoRE discovery machine could easily be utilized in other critical research, including the rapid discovery of therapeutics, such as anti-virals. “Given sufficient resources and access to relevant data, POAI’s CoRE-driven Helomics discovery machine could soon be at the forefront of the fight against these new viruses,” POAI’s release noted.

The impact of this collaboration on the healthcare industry – between POAI’s AI expertise and QM’s CoRe platform – looms large. Insilico Medicine and MIT illustrate the critical part AI and ML play in the process of advancing modern medicine. In its announcement, Insilico Medicine shared molecular structures potentially to targeting the key protein of 2019nCoV. “By making these structures available to the general public, Insilico hopes those who are interested in finding a potential treatment for this viral infection could synthesize and test these molecules,” the announcement said (http://ibn.fm/yYhLv). Insilico will also “synthesize and test up to 100 molecules using its own resources and the resources generously offered by its closest partners, to contribute to the global effort.”

For its part, MIT used an MI algorithm to identify a powerful new antibiotic compound that “killed many of the world’s most problematic disease-causing bacteria, including some strains that are resistant to all known antibiotics,” MIT researchers announced (http://ibn.fm/0sxWn). “It also cleared infections in two different mouse models. The computer model, which can screen more than a hundred million chemical compounds in a matter of days, is designed to pick out potential antibiotics that kill bacteria using different mechanisms than those of existing drugs.” As healthcare industry leaders continue to harness the power of AI and ML technologies to improve patient outcomes, the demand for reliable, data-rich platforms like that of POAI is only expect to grow.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven predictive models of tumor drug repose to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Pioneering supplier-to-pharmacy tech platform builder Trxade Group Inc. helps small, community-based pharmaceutical businesses be competitive with larger chains by sourcing drugs at discount prices and promoting transparency in business operations
• Trxade Group has been developing its subscribers’ access to licensed medical professionals through telehealth services that are both convenient to the patient and significant in their ability to limit the number of people visiting hospitals and offices
• Amid the sweeping, deadly impact of the seasonal flu and the rising novel coronavirus epidemic, Trxade’s online access to physicians is a timely preventative service
• Trxade Group Inc. recently announced its uplisting to the Nasdaq Capital Market and rang the exchange’s opening bell, changing its ticker from ‘TRXD’ to ‘MEDS’
• The company’s network of pharmaceutical partners continues to grow, serving a large percentage of the nation’s 24,000 independent pharmacies

Innovative B2B health services provider Trxade Group Inc. (NASDAQ: MEDS) is helping to reduce exposure to deadly viruses sweeping the planet through the patient empowerment actions of its wholly owned subsidiaries.

As seasonal flu virus infections continue to claim the lives of tens of thousands of Americans and hospitalizes hundreds of thousands of people worldwide (http://ibn.fm/svaWn), the rise and spread of the novel coronavirus COVID-19 has drawn attention to international measures to stop a deadly, vaccine-less illness by first locking down an entire province (in China), and most recently an entire nation (in Italy), while other communities worldwide close public gathering venues or attempt to assure attendees that adequate health measures are being taken to limit their exposure to such viruses (http://ibn.fm/8m08C).

Trxade Group’s support of community-based, independent pharmacies, as well as the acquisition of Community Specialty Pharmacy’s online access operation last year (http://ibn.fm/w1vWg) and the establishment of the “Bonum Health Hub” online portal initiative this year (http://ibn.fm/M2SBE) seems almost prescient in nature given the viral outbreaks’ impact even on access to hospital facilities and their providers (http://ibn.fm/HSCXs).

On March 10, Trxade Group announced the launch of a new membership service by its virtual healthcare subsidiary Bonum Health and its DelivMeds concierge medication delivery operation. The new service allows subscribers to obtain three premium medical teleconferencing visits and free prescription delivery per month, according to a company news release (http://ibn.fm/BDhhl).

Bonum’s telehealth services utilize patients’ personal smart tech devices in a private, HIPPA compliant manner that delivers access to board-certified physicians from virtually anywhere the patient may choose to be.

“Teleconferencing with a board-certified provider for assurance via online consultation is quick, easy, and relatively inexpensive. These services free patients from unnecessary exposure or resorting to urgent care facilities and hospital emergency rooms,” Trxade Group’s news release states. “With the seasonal flu outbreaks and the current coronavirus surge, patients are quick to brush off common symptoms, including cough, fever and body aches, as signs of a common cold; Telemedicine removes the barrier of self-doubt and complacency in the current climate of world-wide viral infections.”

Trxade Group is building a growing platform of integrated drug procurement, delivery and healthcare services to facilitate price transparency and increased profit margins for independent pharmacies within its network as well as pharmaceutical product sellers.

The company recently uplisted its common stock to the Nasdaq Capital Market, while also announcing it expected gross proceeds of $5.2 million from the sale of common stock in a public offering (http://ibn.fm/Nr5uo).

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

• InsuraGuest Technologies provides travel lodging insurance designed as a stop-gap measure to protect travelers and the establishments where they stay in cases where existing policies may not provide coverage
• The company resumed trading on the TSX Venture Exchange on Friday, Feb. 28 at the market’s opening
• InsuraGuest’s ticker will now be ISGI, following a capital consolidation resolution approved by shareholders in November that has been accepted by the TSX exchange
• InsuraGuest is expanding the reach of its proprietary technology throughout the United States, Europe and the United Kingdom, with expectations to enter Asia in mid-2020
• InsuraGuest’s policy, underwritten by Crum & Forster companies, provides first-response protection in cases of in-room property damage, lost or stolen goods, accidental medical expenses, and accidental death and dismemberment at the lodging site up to the policy limits

Supplemental travel accommodations insurance provider InsuraGuest Technologies Inc. (TSX.V: ISGI) resumed trading on the TSX Venture Exchange at the market’s opening on Friday, February 28, under ticker symbol ‘ISGI’.

The name change and consolidation of capital follows a resolution voted on by shareholders at a special meeting held November 29 in which the shareholders approved the company’s acquisition of all of InsuraGuest’s shares for a consideration of 21,080,992 shares, 5,180,000 replacement warrants, 30,354,635 performance warrants and 700,000 options of the company, which the TSX exchange has accepted (http://ibn.fm/1EPIP).

InsuraGuest has been expanding the reach of its proprietary insurtech software platform nationwide in the United States, has entered Europe and the United Kingdom, and expects to launch into Asia by mid-year in 2020. Its platform is adaptable to technology used by the industry’s players, ensuring coverage is governed by a single software system.

The company’s technology is designed to help sustain the travel lodging industry, providing a specialized Hospitality Liability insurance coverage policy to businesses such as hotels, vacation rentals and Airbnb-type residences that are redefining how travelers and tourists take care of their sleep and comfort needs while away from home.

InsuraGuest’s Hospitality Liability policy is a stop-gap product sold to the lodging facility and then included with the facility’s services provided to the customer for a nightly fee. It offers a first line of defense for both the property and the guest in case of personal property theft in the lodging site, as well as accidental in-room damage, accidental medical expense, and accidental death and dismemberment while at the site up to the policy limits, as underwritten by Crum & Forster companies.

Travelers may otherwise find that property owners’ short-term rental insurance policies don’t protect the property’s guests, or that their own travel insurance and homeowner policies fall short of their needs away from home. Airbnb offers a $1 million property damage coverage policy to its sites, but a number of customers have argued in lawsuits that the company has fallen short of its obligations when the need arose (http://ibn.fm/BKvoD).

“Currently, the biggest issue in the vacation rental industry is about standards, and safety and security compliance. Until now, there has been very little guidance for property managers and owners as to how to operate their properties with best practice when it comes to guest safety and security,” Canadian rental certification business founder Wolf Wörster stated in a Viva Glam magazine article on the industry (http://ibn.fm/pVHof).

For more information, visit the company’s website at www.InsuraGuest.com

NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• Leadership team brings collaborative experience from technology, finance and social-media giants
• After products achieve top-selling status, PLUS moves forward into new nationwide markets
• PLUS products available in more than 360 licensed retailers across California; set to launch new wellness/relief and recreational categories for 2020

Offering some of the best-selling cannabis products found in California, Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) continues to make gains in achieving its goal of becoming the top brand in cannabis-infused products. With a world-class management team drawing on valuable experience working with top firms like Facebook, UBS, Uber, the Wonderful Company & Popchips, the company continues to balance rapid expansion and risk management – all while maintaining focus on building a brand, developing customer loyalty and securing a top position in the hyper growth cannabis industry.

The PLUS leadership team spans a wide range of expertise, work experience and industry exposure. After working at Facebook, CEO Jake Heimark co-founded PLUS. Chief strategy officer Craig Heimark lends high-powered finance expertise to the company gained from his experience at UBS and other similar firms. Managing the company’s finances is CFO Jon Paul, who brings more than 25 years of CFO experience to the team.

Navigating the constantly changing legal framework is chief risk officer Jennifer Tung, utilizing skills and expertise gained from her time spent at Uber and Facebook. Chief Scientific Officer Ari Mackler brings product knowledge to the company from his role as VP of clinical development at the Wonderful Company, as well as his PhD in neuroendocrinology.

Expert collaboration is a mainstay of the PLUS team. A collection of some of the best minds in the industry, the entire PLUS team works creatively to fulfill the company’s vision of dominating the cannabis edibles space by becoming the world’s largest cannabis brand.

The expert management team is combined with an exciting outlook for the space. PLUS’s first objective of developing a winning strategy in California was met with massive success when two of the company’s cannabis gummy products reached top-selling status less than two years after legalization. The company’s continuing strategy to become the world’s strongest cannabis-brand portfolio is moving forward through PLUS’ focused efforts to increase national presence, open up new markets of users and create new products for different needs.

PLUS products are now available in more than 360 licensed retailers across the state of California. The company also recently launched its products in Nevada, one of the nation’s most promising cannabis markets. Two new product offerings in two new categories – wellness/relief and what the company calls “get high/have fun” – are expected to launch in early 2020 as the next strategic step in PLUS’s plan to grow its product portfolio.

For more information, visit the company’s website at www.PlusProducts.com

NOTE TO INVESTORS: The latest news and updates relating to PLPRF are available in the company’s newsroom at http://ibn.fm/PLPRF